"Alzheimer's Market Expected to Expand Beyond Dementia Patients to the 'Asymptomatic Stage'"
Diagnosis Shifts from PET Scans to Blood Tests
Drug Delivery Moves from Intravenous to Subcutaneous Injections
"Convenience and Economic Efficiency Improve, Transforming Management Systems"
Experts predict that the scope of Alzheimer's drug administration will expand from dementia patients to include people who show no symptoms but have seen an accumulation of amyloid beta protein—the key pathological marker of Alzheimer's—in their brains. As diagnosis and drug delivery methods become simpler, it is expected that the treatment-eligible population will broaden.
In academia, there is a growing expectation that the aim of Alzheimer's treatment will shift from simply alleviating symptoms to suppressing disease progression through early diagnosis, and that the timing of interventions will move earlier than it is at present.
At the "Eisai Korea Alzheimer's Disease Media Session" held on the 10th at the Plaza Hotel in Jung-gu, Seoul, panelists are speaking. Eisai Korea
View original imageAt the "Eisai Korea Alzheimer's Disease Media Session" held at Plaza Hotel in Jung-gu, Seoul, on August 10, domestic experts shared these perspectives on changes in the treatment environment for Alzheimer's disease.
Professor Moon Yeonshil, a neurologist at Konkuk University Hospital who spoke at the event, said, "Recently, there have been major improvements in the economic feasibility and convenience of Alzheimer's disease diagnosis and drug administration, and this will significantly transform the systems for disease prevention and management going forward."
Regarding diagnostics, she explained that blood-based tests are becoming more widespread, increasing the likelihood of early detection. Previously, to detect amyloid in Alzheimer's patients, an amyloid PET scan was required, which is not covered by insurance and costs more than 1 million won. The high cost of this test has been cited as a factor lowering early diagnosis rates for the disease. However, in May of last year, the first blood test for Alzheimer's was approved in the United States, and its introduction to Korea is expected soon. This will enable simpler and earlier confirmation of Alzheimer's at a lower cost than before. Professor Moon projected, "While approval criteria will limit use to people aged 55 and older who show symptoms, the test is very likely to be included as an item in general health screenings."
Drug delivery methods are also becoming more convenient for patients. The representative Alzheimer's drug Leqembi (ingredient: lecanemab) previously required patients to receive an intravenous injection every two weeks for 18 months. This constraint was lifted last month, when the U.S. Food and Drug Administration (FDA) approved the subcutaneous injection form of Leqembi for use in the early dosing phase. Now, weekly administration takes just 15 seconds per injection. Its commercial launch in the United States is scheduled for the end of this month. Professor Moon added, "For patients whose condition has stabilized, the dosing interval is being increased from once every two weeks to once a month. The subcutaneous injection type is expected to significantly reduce the burden on both patients and their families."
Experts also forecast that the approach to Alzheimer's in hospitals will shift, moving away from treating the disease after symptoms appear and toward managing risk before onset.
Professor Moon Soyoung, a neurologist at Ajou University Hospital who also spoke at the event, commented, "Currently, Leqembi is indicated for patients with mild cognitive impairment and early-stage Alzheimer's dementia, but clinical trials are underway involving people who have normal cognitive function but show amyloid buildup in their brains (CU). We may reach a future where those in their 50s are tested annually, and if amyloid is detected, they can receive a single injection." This means that, in addition to patients with dementia, those at high risk may also be brought under management, potentially greatly expanding the scope of the Alzheimer's treatment market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Alzheimer's market continues to grow. The number of dementia patients in Korea reached 970,000 last year and is about to surpass the 1 million mark. The annual social cost of caring for these patients amounts to 23 trillion won. The Central Dementia Center estimates that this cost will rise to 75 trillion won by 2040.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.